中国免疫学杂志2024,Vol.40Issue(4) :741-751.DOI:10.3969/j.issn.1000-484X.2024.04.012

骨形态发生蛋白拮抗剂GREM1作为胃癌肿瘤微环境免疫活性预测指标的临床价值

Clinical value of bone morphogenetic protein antagonist GREM1 as an immuno-active indicator in tumor microenvironment of gastric cancer

张旭东 李晓宁 崔海康 杨希 杨兰 张文杰
中国免疫学杂志2024,Vol.40Issue(4) :741-751.DOI:10.3969/j.issn.1000-484X.2024.04.012

骨形态发生蛋白拮抗剂GREM1作为胃癌肿瘤微环境免疫活性预测指标的临床价值

Clinical value of bone morphogenetic protein antagonist GREM1 as an immuno-active indicator in tumor microenvironment of gastric cancer

张旭东 1李晓宁 1崔海康 1杨希 1杨兰 2张文杰2
扫码查看

作者信息

  • 1. 石河子大学医学院病理系/新疆地方与民族高发病教育部重点实验室,石河子 832002
  • 2. 石河子大学医学院病理系/新疆地方与民族高发病教育部重点实验室,石河子 832002;石河子大学医学院第一附属医院病理科,石河子 832002
  • 折叠

摘要

目的:筛选出可预测胃癌(GC)肿瘤微环境(TME)免疫活性的预后基因.方法:收集55例GC患者术后石蜡组织标本及其对应的癌旁组织;从TCGA数据库和GEO数据库中共下载了976例GC患者的转录组数据及临床数据;采用估计算法(ESTIMATE)和反卷积算法(CIBERSORT)分别评估各样本中免疫/基质得分及免疫细胞浸润程度;R语言中的"limma"包筛选差异表达基因(DEGs);采用单变量Cox回归分析筛选具有预后价值的DEGs;qRT-PCR检测枢纽基因mRNA的表达情况;GSEA探究GREM1的潜在生物学功能.采用TISIDB和CellMiner数据库分析GREM1与免疫特征分子及药物敏感性的相关性.结果:免疫评分与GC患者的预后呈正相关;在免疫得分和基质得分高、低分组中共筛选出40个共享的TME相关DEGs;通过对DEGs进行单变量Cox回归分析,得到GREM1、SFRP2、CYP1B1和MGP共4个具有预后意义的共享DEGs.通过比较基因在肿瘤与癌旁组织的表达差异及与免疫微环境的密切程度,发现GREM1最可能对TME中的免疫重塑发挥作用;GREM1的表达与GC患者的临床病理特征(TNM)呈正相关,而与生存率呈负相关;GSEA结果显示GREM1高表达组主要富集于免疫相关通路,GREM1的表达与M2型巨噬细胞呈正相关,而与CD8+T细胞呈负相关;GREM1与免疫抑制剂TGF-β1、免疫增强剂ENTPD1、趋化因子CCL14及受体CCR2呈正相关;GREM1高表达的肿瘤细胞对抗肿瘤药物维莫德吉的治疗敏感性最强.结论:GREM1可作为反映GC TME免疫抑制状态的临床指标.

Abstract

Objective:To screen prognostic genes as indicators for predicting immunoactive in tumor microenvironment(TME)of gastric cancer(GC).Methods:Paraffin tissue specimens and corresponding paracancer tissues were collected from 55 patients with GC.Total 976 GC transcriptome RNA-Seqs and clinical datasets were obtained from TCGA and GEO databases.Infiltra-tion status of immune cells and Immune/Stormal scores were calculated using the ESTIMATE and CIBERSORT algorithm.R package"limma"was performed to selected differentially expressed genes(DEGs).Univariate Cox regression analysis was used to determine prognostic factors of DEGs.qRT-PCR was demonstrated to detect mRNA expression of the hub genes.Potential biological functions of GREM1 were investigated by GSEA.Correlations of GREM1 with immune signature molecules and drug susceptibility were investigated by TISIDB and CellMiner database.Results:Immune Score was positively correlated with improved outcomes of GC patients.A total of 40 shared TME-related DEGs were selected in the high and low groups of Immune Score and Stromal Score.Four survival-related DEGs were obtained by Cox analysis,which were GREM1,SFRP2,CYP1B1 and MGP.By comparing the difference of gene expres-sion in tumor and adjacent tissues and the degree of affinity with immune microenvironment,it was found that GREM1 was most likely to play a role in immune remodeling in TME;expression of GREM1 was positively correlated with clinicopathological features(TNM),while negatively correlated with survival time of GC patients.GSEA results showed that GREM1 high-expression group were mainly enriched in immune-related active genomes.Besides,GREM1 expression was positively correlated to M2 macrophages,while negatively correlated to CD8+T cells.GREM1 was also positively associated with immunosuppressor TGF-β1,immunopotentiator ENT-PD1,chemokine CCL14 as well as receptor CCR2.Moreover,GC patients with high expression of GREM1 might more sensitive to drug Vismodegib therapy.Conclusion:GREM1 can regard as an immunosuppressive clinical indicator in TME of GC.

关键词

GREM1/胃癌/肿瘤浸润性免疫细胞/肿瘤免疫微环境/预后因子

Key words

GREM1/Gastric cancer/Tumor-infiltrating immune cells/Tumor immune microenvironment/Prognostic factors

引用本文复制引用

出版年

2024
中国免疫学杂志
中国免疫学会,吉林省医学期刊社

中国免疫学杂志

CSTPCDCSCD北大核心
影响因子:0.926
ISSN:1000-484X
参考文献量44
段落导航相关论文